For healthcare professionals only

Research Article

Benefits and risks of protracted treatment with human recombinant erythropoietin in patients having haemodialysis.

Br Med J (Clin Res Ed) 1987; 295 doi: https://doi.org/10.1136/bmj.295.6605.1017 (Published 24 October 1987) Cite this as: Br Med J (Clin Res Ed) 1987;295:1017